ECTRIMS2023

ECTRIMS 2023: Most on Zeposia see slower disability progression

More than three-quarters of people with relapsing forms of multiple sclerosis (MS) who received Zeposia (ozanimod) in the RADIANCE clinical trial and its extension study still haven’t experienced confirmed disability progression after eight years of follow-up, new data shows. Among those who progressed, about half of disability progression…

ECTRIMS 2023: New research may help explain EBV and MS link

New research by scientists in Austria may shed light on the link between theĀ Epstein-Barr virus (EBV) andĀ multiple sclerosis (MS), and explain why only some people infected with EBV ā€” previously found to raise the risk of MSĀ by 32 times ā€” go on to develop the neurodegenerative disorder. Distinct…

ECTRIMS 2023: Fenebrutinib lowers new lesions in relapsing MS

Treatment with the investigational therapy fenebrutinib significantly reduced the number of new inflammatory lesions visible on MRI scans in people with relapsing forms of multiple sclerosis (MS). Pharmacological data from the study suggest the anti-inflammatory experimental medication can get into the brain and spinal cord at levels high…

ECTRIMS 2023: More disease activity when treatment stopped

A clinical trial that was testing if treatments for multiple sclerosis (MS) could be discontinued in people with stable disease was terminated early after several patients who stopped treatment saw new disease activity. The findings support the continued use of disease-modifying therapies (DMTs) even by those who haven’t…

ECTRIMS 2023: Personalized dosing of Tysabri shows good efficacy

A personalized dosing schedule for Tysabri (natalizumab) that aims to maintain blood levels of the drug above a certain threshold seems to be just as effective for controlling disease activity in relapsing-remitting multiple sclerosis (RRMS) as the approved every-four-week dosing schedule. That’s according to interim data from an…

ECTRIMS 2023: Early high-efficacy DMTs may help slow MS disability

People with relapsing-remitting multiple sclerosis (RRMS) who had an early start on high-efficacy disease-modifying therapies (DMTs) experience slower disability progression compared with those on escalation treatment, according to recent research. The study, which followed patients for up to 10 years, supports starting high-risk RRMS patients on highly effective…

ECTRIMS 2023: Under-the-skin Ocrevus found to be powerful in MS

A new under-the-skin formulation of Ocrevus (ocrelizumab) ā€” administered in 10 minutes ā€” is at least as effective as the approved intravenous, or into-the-vein, formulation among people with multiple sclerosis (MS), according to new clinical trial data. Most people given either the new subcutaneous formulation or the intravenous…

ECTRIMS 2023: EBV may trigger attack on brain protein ANO2

Infection with the Epstein-Barr virus (EBV) may prime the immune system to accidentally attack a brain protein called ANO2, new research shows. The findings may explain how EBV infection can lead to developing multiple sclerosis (MS), at least in some patients. Daniel Jons, PhD, a scientist at the…

ECTRIMS 2023: Vidofludimus calcium lowers RRMS nerve damage

Six months of treatment with the experimental oral therapy vidofludimus calcium (IMU-838) led to significant reductions in a marker of nerve damage among people withĀ relapsing-remitting multiple sclerosis (RRMS), according to a new analysis of data from a Phase 2 clinical trial. Previous data indicated the therapy significantly reduced…